Livforsakringsbolaget Skandia Omsesidigt cut its position in shares of Edwards Lifesciences Corp (NYSE:EW) by 12.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 9,380 shares of the medical research company’s stock after selling 1,300 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Edwards Lifesciences were worth $1,057,000 as of its most recent filing with the SEC.
Several other hedge funds have also recently modified their holdings of EW. ETF Managers Group LLC acquired a new stake in shares of Edwards Lifesciences in the second quarter worth $112,000. MPS Loria Financial Planners LLC acquired a new stake in Edwards Lifesciences during the second quarter valued at $140,000. Dupont Capital Management Corp bought a new position in Edwards Lifesciences during the third quarter valued at about $142,000. Salem Investment Counselors Inc. raised its holdings in Edwards Lifesciences by 16.3% during the second quarter. Salem Investment Counselors Inc. now owns 1,419 shares of the medical research company’s stock valued at $168,000 after buying an additional 199 shares in the last quarter. Finally, Sun Life Financial INC raised its holdings in Edwards Lifesciences by 13,827.3% during the second quarter. Sun Life Financial INC now owns 1,532 shares of the medical research company’s stock valued at $181,000 after buying an additional 1,521 shares in the last quarter. Institutional investors own 81.11% of the company’s stock.
In other Edwards Lifesciences news, VP Robert W.A. Sellers sold 12,020 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $131.03, for a total value of $1,574,980.60. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences stock in a transaction on Monday, January 29th. The stock was sold at an average price of $127.24, for a total transaction of $674,372.00. Following the transaction, the vice president now owns 24,908 shares in the company, valued at approximately $3,169,293.92. The disclosure for this sale can be found here. Insiders have sold a total of 175,940 shares of company stock worth $20,049,578 in the last quarter. 2.13% of the stock is currently owned by company insiders.
A number of research firms have recently commented on EW. Cowen reiterated a “buy” rating and issued a $150.00 price objective on shares of Edwards Lifesciences in a research note on Thursday, February 1st. Zacks Investment Research upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $145.00 price target on the stock in a research note on Thursday. JMP Securities boosted their price target on Edwards Lifesciences from $135.00 to $140.00 and gave the company a “market outperform” rating in a research note on Friday, February 2nd. Canaccord Genuity reaffirmed a “buy” rating and set a $174.00 price objective (up from $140.00) on shares of Edwards Lifesciences in a report on Friday, February 2nd. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $155.00 price objective on shares of Edwards Lifesciences in a report on Friday, February 2nd. Three research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $141.15.
Shares of Edwards Lifesciences Corp (NYSE:EW) traded up $0.62 during trading hours on Monday, reaching $126.89. 1,159,122 shares of the company traded hands, compared to its average volume of 1,370,000. Edwards Lifesciences Corp has a twelve month low of $89.20 and a twelve month high of $138.48. The firm has a market cap of $26,850.00, a P/E ratio of 44.06, a P/E/G ratio of 1.86 and a beta of 0.63. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.81 and a quick ratio of 1.41.
Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, February 1st. The medical research company reported $0.94 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.91 by $0.03. Edwards Lifesciences had a net margin of 18.11% and a return on equity of 27.69%. The firm had revenue of $888.50 million for the quarter, compared to analysts’ expectations of $868.45 million. During the same period in the prior year, the firm earned $0.75 EPS. The business’s revenue was up 15.7% on a year-over-year basis. equities research analysts anticipate that Edwards Lifesciences Corp will post 4.49 earnings per share for the current year.
Edwards Lifesciences declared that its Board of Directors has authorized a share repurchase program on Thursday, December 7th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the medical research company to buy shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.
WARNING: “Livforsakringsbolaget Skandia Omsesidigt Has $1.06 Million Position in Edwards Lifesciences Corp (NYSE:EW)” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/12/edwards-lifesciences-corp-ew-position-trimmed-by-livforsakringsbolaget-skandia-omsesidigt.html.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.